OR WAIT null SECS
August 18, 2021
Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.
August 17, 2021
Visual benefit is not seen during first 2 years of Protocol W study.
August 16, 2021
Considerations for treating retinal disorders with sustained-release drug delivery implants in an effort to address current treatment challenges in the field.
Dexamethasone implant, aflibercept offer a safe treatment option for diabetic macular edema.
August 14, 2021
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
August 11, 2021
An overview of delivery systems under investigation for retinal disorders and implications for future use.
August 10, 2021
Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.
August 09, 2021
A discussion highlighting new agents under investigation for retinal disorders and implications for future use based on data revealed in more recent clinical trials.
August 04, 2021
Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.
August 02, 2021
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
